Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan

Among treatment modalities for lung cancer, the most promising therapy is the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and gefitinib, the two first‐generation EGFR‐TKIs, exhibit significant clinical responses for patients with lung adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chia‐Hao, Lee, Chih‐Hsin, Ko, Jen‐Chung, Chang, Lih‐Yu, Lee, Ming‐Chia, Wang, Jann‐Yuan, Yu, Chong‐Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504326/
https://www.ncbi.nlm.nih.gov/pubmed/28639751
http://dx.doi.org/10.1002/cam4.1121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504326/
https://www.ncbi.nlm.nih.gov/pubmed/28639751
http://dx.doi.org/10.1002/cam4.1121

Ejemplares similares